Mereo Biopharma
Biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $50.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 102 % | 140 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (56 %) | - | (240 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 35 % | - | (295 %) | - | (84 %) | (56 %) | 6 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 65 % | - | 174 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Mereo BioPharma is a biopharmaceutical company focused on developing innovative therapies for patients suffering from rare diseases. Operating in the healthcare and biotechnology market, Mereo BioPharma targets unmet medical needs by advancing a robust portfolio of clinical-stage products. The company's business model revolves around the research, development, and commercialization of novel treatments, primarily through strategic partnerships and collaborations with other pharmaceutical entities. Revenue is generated through licensing agreements, milestone payments, and eventual product sales. Mereo BioPharma serves a niche market of patients with rare and orphan diseases, aiming to provide better treatment options and improve their quality of life. The company is committed to scientific excellence and regulatory compliance, ensuring that its therapies meet the highest standards of safety and efficacy.
Keywords: biopharmaceutical, rare diseases, innovative therapies, clinical-stage products, healthcare, biotechnology, strategic partnerships, licensing agreements, orphan diseases, patient care.